| 产品详情 |
| Edit |   |
|---|
| Product Name | EMT6/AR1 |
|---|
| Description | EMT6/AR1 was derived from the mouse mammary tumour cell line EMT6/P by growth in increasing amounts of doxorubicin over a period of 8 weeks. The cell line showed a 40-fold greater resistance to doxorubicin, which is also known as adriamycin. The line was reported to express a classical multi-drug resistance (MDR) phenotype with hyperexpression of membrane P-glycoprotein and a spectrum of cross-resistance e.g. against vincristine and colchicine. Overexpression of CP22 (sorcin) and mdr 1a gene was reported. Cells were shown to have a reduced intracellular drug accumulation and exhibit a doubling time of 12-15 hours. It is recommended to culture the cells without drug after resuscitation until the first passage. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | n/a |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | CSC-C9497J |
|---|
| Price | |
|---|
| Order / More Info | EMT6/AR1 from CREATIVE BIOARRAY |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|